HDAC9 and myeloproliferative neoplasm: While pan-HDAC inhibitors (e.g., vorinostat, givinostat, pracinostat, panobinostat) have been assessed in clinical trials and some have displayed efficacy in MPN patients, toxicity concerns may limit their potential (119–126).